The reward/reinforcement circuitry of the mammalian brain consists of synaptically interconnected neurons associated with the medial forebrain bundle, linking the ventral tegmental area, nucleus accumbens, and ventral pallidum. Electrical stimulation of this circuit supports intense selfstimulation in animals and, in humans, produces intense pleasure or euphoria. This circuit is strongly implicated in the neural substrates of drug addiction and in such addiction-related phenomena as withdrawal dysphoria and craving. This circuit is also implicated in the pleasures produced by natural rewards (e.g., food, sex). Cannabinoids are euphorigenic in humans and have addictive liability in vulnerable persons, but were long considered ''anomalous'' drugs of abuse, lacking pharmacological interaction with these brain reward substrates. It is now clear, however, that cannabinoids activate these brain substrates and influence reward-related behaviors. From these actions, presumably, derive both the abuse potential of cannabinoids and the possible clinical efficacy in dysphoric states. 1998 Academic Press
The past decade has witnessed a thoroughly remarkable advance in our understanding of the action of marijuana, other cannabis constituents, and cannabinoid-like drugs on brain and behavior (1-3). This cascade of increased understanding stems in large measure from the discovery that cannabinoids interact with specific G-protein-coupled brain receptors to modulate neuronal function and behavior (4-10). It is now clear that cannabinoids act through both a central (11) cannabinoid receptor (termed the CB1 receptor) and a peripheral (12) receptor (CB2), both of which have been characterized at the molecular level (11-13). The CB1 receptor is widely distributed throughout the brain, with especially high densities in the basal ganglia, hippocampus, and cerebellum (14,15). Worthy of note is the fact that CB1 receptors occur in significant densities in brain areas associated with reward and reinforcement functions, including the ventral striatum and ventral mesencephalon (14,15) (see below for implication of these areas in brain reward functions). Functional variants and isoforms of these endogenous cannabinoid receptors may well exist in the body (16, 17) . An exceedingly wide variety of selective ligands with partial or full agonist action at cannabinoid receptors has been developed (18-27) (many by Pfizer Central Research and by Sanofi Winthrop, Inc.), allowing a formidable array of pharmacological agents to probe cannabinoid receptor-mediated neuronal events and behaviors, as well as conducting structureactivity studies. Highly selective and potent antagonists have also been developed for both the CB1 (28,29) and the CB2 (30) receptors. At least two endogenous ligands, arachidonyl ethanolamide (anandamide) (3,31,32) and 2-arachidonylglycerol (3,32-34) , have been identified as binding to cannabinoid receptors and fulfilling requirements for neurotransmitter or neuromodulator functions. Anandamide-discovered in 1992 and thus studied longer-has in particular been shown to bind to cannabinoid receptors, to be synthesized and released by neurons, to be subject to a high-affinity reuptake process, and to be enzymatically degraded in brain (35) (36) (37) (38) (39) . When administered to laboratory animals, anandamide shows a classic constellation of
